Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta...
Main Authors: | Fajun Pei, Yang Yu, Bin Dong, Hui Guan, Xinzhe Dong, Fen Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.694545/full |
Similar Items
-
GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01) -
Retrospective Analysis of Pemetrexed-based Chemotherapy Regimens on Mid-elderly Non-Hodgkin's Lymphoma
by: WEN Tingyu, et al.
Published: (2020-02-01) -
Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era
by: Annabel M. Follows, et al.
Published: (2022-11-01) -
Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma
by: Roiya Farhan, MBBS, et al.
Published: (2020-12-01) -
The Treatment of Non-Hodgkin's Lymphomas
by: David J. Straus
Published: (2023-08-01)